![]() ![]() Clinical trials of multiple projects including those under the R&D Agreement are expected to start in the early 2020s. Since the signing of the R&D Agreement last year, the companies have advanced joint research and development by leveraging respective strengths of the parties: iota with its core technology and world-class talent in the field of bioelectronics and Astellas with its expertise and deep understandings in biology and diseases as well as experiences in advancing medical solutions from research to market. In contrast, iota's bioelectronic devices can be implanted through a less invasive operative procedure and offer promise for a new healthcare solution with improved effectiveness and reduced physical burden for the patients during and after surgery. This has made size reduction difficult and has often resulted in highly invasive implant procedures. This resulted in the ability to develop unprecedentedly ultra-small (millimeter sized) battery-free, wireless implantable medical devices.Ĭonventional implantable medical devices require batteries for power supply and wires or large electronic circuits to facilitate communications. iota’s innovative technology uses ultrasound both to power the devices and to enable wireless communication. Iota is a start-up company founded in 2017 by Michel Maharbiz and Jose Carmena, each of whom has demonstrated outstanding achievement in the bioelectronics field. This acquisition, which contemplates the utilization of iota’s unique technology as a platform to advance innovation in the bioelectronics field, is expected to accelerate Astellas’ Rx+ ® business not only by expediting the Rx+ ® projects previously covered under the R&D Agreement but also by allowing exploration of other applications of iota’s unique bioelectronics technology for new target diseases and developing new technologies. Through the acquisition of iota, Astellas will acquire iota’s unique bioelectronics technology and world-class talent. In carrying out the activities contemplated under the R&D Agreement, the companies have evaluated detailed specifications for implantable medical devices focused on multiple diseases with high unmet medical needs. subsidiary, and iota have entered into a Merger Agreement pursuant to which Astellas will acquire iota.Īstellas and iota previously entered into a Research and Development Agreement in August 2019 (the “R&D Agreement”) to jointly conduct research and development activities associated with iota’s ultrasonic-powered bioelectronic devices (also known as “neural dust”) in a number of indications. and Jose Carmena, Ph.D., “iota”) announced today that Astellas through a U.S. ![]() (Co-founders and Co-CEOs: Michel Maharbiz, Ph.D. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Iota Biosciences, Inc. TOKYO and Berkeley, CA., OctoAstellas Pharma Inc. Accelerate Rx + ® business by acquiring innovative technology for ultra-small implantable medical devices and world-class talent in the bioelectronics field.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |